clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Tuberculosis, Spinal D014399 1 associated lipids
Hypoproteinemia D007019 1 associated lipids
Myxoma D009232 1 associated lipids
Epilepsy, Partial, Motor D020938 1 associated lipids
Cutaneous Fistula D017577 1 associated lipids
Kleine-Levin Syndrome D017593 1 associated lipids
Granuloma, Plasma Cell D006104 1 associated lipids
Empyema, Tuberculous D004654 1 associated lipids
Tuberculosis, Ocular D014392 1 associated lipids
Encephalomyelitis, Acute Disseminated D004673 1 associated lipids
Serositis D012700 1 associated lipids
Euthyroid Sick Syndromes D005067 1 associated lipids
Immune Reconstitution Inflammatory Syndrome D054019 1 associated lipids
Glossitis, Benign Migratory D005929 1 associated lipids
Parotid Diseases D010305 1 associated lipids
Sacroiliitis D058566 1 associated lipids
Achlorhydria D000126 1 associated lipids
Extensively Drug-Resistant Tuberculosis D054908 1 associated lipids
Pseudomyxoma Peritonei D011553 1 associated lipids
Eye Infections D015817 1 associated lipids
Upper Extremity Deep Vein Thrombosis D056824 1 associated lipids
Gastritis, Hypertrophic D005758 1 associated lipids
Buruli Ulcer D054312 1 associated lipids
Hyperemesis Gravidarum D006939 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Leprosy, Paucibacillary D056005 2 associated lipids
Typhoid Fever D014435 2 associated lipids
Diphtheria D004165 2 associated lipids
Soft Tissue Infections D018461 2 associated lipids
Empyema, Pleural D016724 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Mastoiditis D008417 2 associated lipids
Periodontal Abscess D010508 2 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Duodenogastric Reflux D004383 2 associated lipids
Iritis D007500 2 associated lipids
Parotid Neoplasms D010307 2 associated lipids
IgA Deficiency D017098 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Chlamydial Pneumonia D061387 2 associated lipids
Leprosy, Lepromatous D015440 2 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Discitis D015299 2 associated lipids
Iris Diseases D007499 2 associated lipids
Tooth, Nonvital D019553 2 associated lipids
Tuberculosis, Avian D014379 2 associated lipids
Immunoproliferative Small Intestinal Disease D007161 2 associated lipids
Barrett Esophagus D001471 3 associated lipids
Giardiasis D005873 3 associated lipids
Central Nervous System Protozoal Infections D020808 3 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Empyema D004653 3 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Tenosynovitis D013717 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Pityriasis Rosea D017515 3 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Ureteral Diseases D014515 3 associated lipids
Sporotrichosis D013174 3 associated lipids
Hernia, Hiatal D006551 3 associated lipids
Fusobacterium Infections D005674 3 associated lipids
Ecchymosis D004438 3 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Bartonella Infections D001474 3 associated lipids
Paronychia D010304 3 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Fractures, Open D005597 3 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Scrub Typhus D012612 3 associated lipids
Mycetoma D008271 4 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Cysts D003560 4 associated lipids
Duodenitis D004382 4 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Foot Diseases D005534 4 associated lipids
Ergotism D004881 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Rodent Diseases D012376 4 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pleural Diseases D010995 4 associated lipids
Parotitis D010309 4 associated lipids
Psittacosis D009956 4 associated lipids
Prurigo D011536 4 associated lipids
Confusion D003221 4 associated lipids
Lymphangitis D008205 4 associated lipids
Erythema Nodosum D004893 5 associated lipids
Pyelonephritis D011704 5 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Liu WZ et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10102964
Huang J and Hunt RH Clarithromycin-based triple therapies. 1999 Aliment. Pharmacol. Ther. pmid:10102978
Kohyama T et al. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. 1999 Antimicrob. Agents Chemother. pmid:10103198
Dempsey CL et al. Drug usage evaluation: clarithromycin as sequential therapy. 1993 Hosp Formul pmid:10130382
Craig AM et al. Decision analysis of Helicobacter pylori eradication therapy using omeprazole with either clarithromycin or amoxicillin. 1996 Pharmacoeconomics pmid:10160472
Gimenez Garcia R et al. Fish tank granuloma: response to treatment with clarithromycin. 1999 J Eur Acad Dermatol Venereol pmid:10188167
Fournier S et al. Effect of adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium complex septicemia in AIDS patients. 1999 Eur. J. Clin. Microbiol. Infect. Dis. pmid:10192709
Gómez-Gil E et al. Clarithromycin-induced acute psychoses in peptic ulcer disease. 1999 Eur. J. Clin. Microbiol. Infect. Dis. pmid:10192720
Rosário M et al. [Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population]. 1998 Acta Med Port pmid:10192979
Lee CK et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. 1999 Vaccine pmid:10195786
Verbanck JJ et al. Campylobacter jejuni II peritonitis in a CCPD patient: cure by oral clarithromycin. 1999 Jan-Feb Perit Dial Int pmid:10201350
Sonnenberg A et al. The effect of antibiotic therapy on bleeding from duodenal ulcer. 1999 Am. J. Gastroenterol. pmid:10201462
Smoot DT et al. Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10201463
Laine L et al. Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. 1999 Am. J. Gastroenterol. pmid:10201465
Zhou Q et al. CYP2C19 genotypes and omeprazole metabolism after single and repeated dosing when combined with clarithromycin. 1999 Eur. J. Clin. Pharmacol. pmid:10206083
Miwa H et al. Efficacy of 1 week omeprazole or lansoprazole-amoxycillin-clarithromycin therapy for Helicobacter pylori infection in the Japanese population. 1999 J. Gastroenterol. Hepatol. pmid:10207779
Henry DC et al. Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group. 1999 Clin Ther pmid:10211537
McConnell SA and Amsden GW Review and comparison of advanced-generation macrolides clarithromycin and dirithromycin. 1999 Pharmacotherapy pmid:10212011
Dubois J and St-Pierre C In vitro activity of gatifloxacin, compared with ciprofloxacin, clarithromycin, erythromycin, and rifampin, against Legionella species. 1999 Diagn. Microbiol. Infect. Dis. pmid:10212753
Clifford K et al. Double-blind comparative trial of ciprofloxacin versus clarithromycin in the treatment of acute bacterial sinusitis. Sinusitis Infection Study Group. 1999 Ann. Otol. Rhinol. Laryngol. pmid:10214783
Kashimura H et al. Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. 1999 Aliment. Pharmacol. Ther. pmid:10215732
Lee JM et al. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. 1999 Aliment. Pharmacol. Ther. pmid:10215733
Neville PM et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. 1999 Aliment. Pharmacol. Ther. pmid:10215734
Hoffman JS et al. Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. 1999 Aliment. Pharmacol. Ther. pmid:10215735
Abbott GW et al. MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. 1999 Cell pmid:10219239
van der Hulst RW et al. [Treatment of Helicobacter pylori infections]. 1999 Ned Tijdschr Geneeskd pmid:10221109
Khan AA et al. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. 1999 Int. J. Antimicrob. Agents pmid:10221415
Sato K and Tomioka H Antimicrobial activities of benzoxazinorifamycin (KRM-1648) and clarithromycin against Mycobacterium avium-intracellulare complex within murine peritoneal macrophages, human macrophage-like cells and human alveolar epithelial cells. 1999 J. Antimicrob. Chemother. pmid:10223590
Garey KW et al. Lack of effect of zafirlukast on the pharmacokinetics of azithromycin, clarithromycin, and 14-hydroxyclarithromycin in healthy volunteers. 1999 Antimicrob. Agents Chemother. pmid:10223928
Fish DN and Abraham E Pharmacokinetics of a clarithromycin suspension administered via nasogastric tube to seriously ill patients. 1999 Antimicrob. Agents Chemother. pmid:10223952
Bergman KL et al. Antimicrobial activities and postantibiotic effects of clarithromycin, 14-hydroxy-clarithromycin, and azithromycin in epithelial cell lining fluid against clinical isolates of haemophilus influenzae and Streptococcus pneumoniae. 1999 Antimicrob. Agents Chemother. pmid:10223956
Gisbert JP et al. [Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments]. 1999 Med Clin (Barc) pmid:10227015
Gisbert JP [Lansoprazole: a review of its role in Helicobacter pylori eradication therapy]. 1999 Rev Esp Enferm Dig pmid:10231305
Goddard AF et al. Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. 1999 Aliment. Pharmacol. Ther. pmid:10233187
Pilotto A et al. The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. 1999 Aliment. Pharmacol. Ther. pmid:10233191
Hayashi Y et al. Torsades de pointes ventricular tachycardia induced by clarithromycin and disopyramide in the presence of hypokalemia. 1999 Pacing Clin Electrophysiol pmid:10234723
Vakil N and Cutler A Ten-day triple therapy with ranitidine bismuth citrate, amoxicillin, and clarithromycin in eradicating Helicobacter pylori. 1999 Am. J. Gastroenterol. pmid:10235192
Woods GL et al. Multisite reproducibility of results obtained by the broth microdilution method for susceptibility testing of Mycobacterium abscessus, Mycobacterium chelonae, and Mycobacterium fortuitum. 1999 J. Clin. Microbiol. pmid:10325306
Warheker PT et al. Successful treatment of saccular endophthalmitis with clarithromycin. 1998 Eye (Lond) pmid:10326009
Carbon C and Poole MD The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. 1999 J Chemother pmid:10326741
Le Gars L et al. Polyarthralgia-arthritis syndrome induced by low doses of rifabutin. 1999 J. Rheumatol. pmid:10332992
Bocheńska-Marciniak M et al. [Clinical efficacy and safety of spiramycin and clarithromycin in the treatment of outpatients with lower respiratory tract infections]. 1998 Pol. Arch. Med. Wewn. pmid:10335027
Champney WS and Tober CL Superiority of 11,12 carbonate macrolide antibiotics as inhibitors of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells. 1999 Curr. Microbiol. pmid:10341075
Nitu IC et al. Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses. 1999 Clin Lab Haematol pmid:10342075
Abdul Aal GM et al. Resolution of gastritis induced by Helicobacter pylori 4-5 weeks after successful eradication of infection using a triple therapy regimen of pantoprazole, amoxycillin and clarithromycin for one week. 1999 Digestion pmid:10343145
Dajani AI et al. One-week triple regime therapy consisting of pantoprazole, amoxicillin and clarithromycin for cure of Helicobacter pylori-associated upper gastrointestinal diseases. 1999 Digestion pmid:10343146
Sonnenberg A et al. Antibiotic therapy of Helicobacter pylori infection reduces healthcare expenditures related to duodenal ulcer. 1999 Am J Manag Care pmid:10345967
Champney WS and Tober CL Molecular investigation of the postantibiotic effects of clarithromycin and erythromycin on Staphylococcus aureus cells. 1999 Antimicrob. Agents Chemother. pmid:10348746
Debets-Ossenkopp YJ et al. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands. 1999 J. Antimicrob. Chemother. pmid:10350380
Son SW et al. The response of rosacea to eradication of Helicobacter pylori. 1999 Br. J. Dermatol. pmid:10354058